By RICHARD BEALES
With questions raised about the blood-testing company’s technology, its purported $9 billion valuation now looks overestimated.
Published: October 28, 2015 at 12:00AM
from NYT Business Day http://ift.tt/1MRJBCU
from WordPress http://ift.tt/1Whk4YT
via Hadi Aboukhater
No comments:
Post a Comment